Bicycle Therapeutics Announces Topline Phase 1 Data For Zelenectide Pevedotin Plus Pembrolizumab

(RTTNews) - Bicycle Therapeutics plc (BCYC), Monday announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC). The stock is currently up 13%.

The company also announced recent accomplishments and outlined strategic priorities and anticipated milestones for 2025.

"Bicycle Therapeutics made significant advances across all aspects of our business in 2024. Notably, we drove important clinical progress of our targeted therapeutics in solid tumors, including greatly expanding the number of patients who could potentially benefit from our lead therapy zelenectide pevedotin, advanced our emerging pipeline of novel radiopharmaceuticals and strengthened our financial position and operational capabilities to advance our strategic priorities," said CEO Kevin Lee.

Zelenectide pevedotin, a Bicycle Toxin Conjugate, has significant potential to treat Nectin-4 cancers. 65% overall response rate (ORR) (13/20) among all efficacy-evaluable patients, and a 50% ORR (10/20) among patients with confirmed responses.